# SURGE Therapeutics

> SURGE Therapeutics is a Cambridge, Massachusetts clinical-stage biotech building intraoperative immunotherapy: a biodegradable, injectable hydrogel (SURGERx) placed directly into the surgical wound at the moment a tumor is removed. The goal is to turn the body's post-surgical inflammation from immunosuppressive to immunostimulatory and stop residual cancer cells from seeding recurrence and metastasis. Founded on research from Harvard Medical School and led by founder-CEO Michael Goldberg, Ph.D., the company has raised about $58M and is advancing its lead candidate SRG-514 toward a registrational trial in triple-negative breast cancer.

- **Founded:** 2021
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Michael Goldberg (Founder & CEO, Ph.D.)
- **Team size:** Small (~8-15 employees reported)
- **Products:** SURGERx, SRG-514, Intraoperative immunotherapy (bladder cancer program)
- **Notable:** Raised approximately $58M total across Series A ($26M, 2022) and Series B ($32M, 2023), Received FDA clearance of an IND to initiate a Phase 1/2a study of intraoperative immunotherapy in bladder cancer (Jan 2023), Completed Phase 1 dosing of lead candidate SRG-514 with no treatment-related dose-limiting toxicities reported (announced Feb 2026)

## Products & services

- **SURGERx** — An optimized, biodegradable injectable hydrogel platform based on Harvard Medical School research. Placed into the surgical cavity at the time of tumor resection, it concentrates and sustains the release of immunomodulators locally, reprogramming the post-surgical inflammatory response from immunosuppressive to immunostimulatory.
- **SRG-514** — Lead investigational candidate delivering immunotherapy intraoperatively into the resection cavity. Completed Phase 1 dose-escalation dosing in breast cancer patients with no treatment-related dose-limiting toxicities reported; advancing toward a registrational trial in triple-negative breast cancer.
- **Intraoperative immunotherapy (bladder cancer program)** — FDA cleared SURGE's IND to initiate a Phase 1/2a study of its intraoperative immunotherapy approach in bladder cancer, extending the platform beyond breast cancer.

## Achievements

- Raised approximately $58M total across Series A ($26M, 2022) and Series B ($32M, 2023)
- Received FDA clearance of an IND to initiate a Phase 1/2a study of intraoperative immunotherapy in bladder cancer (Jan 2023)
- Completed Phase 1 dosing of lead candidate SRG-514 with no treatment-related dose-limiting toxicities reported (announced Feb 2026)
- Established and named a new therapeutic category: 'The Intraoperative Immunotherapy Company'
- Assembled a top-tier biotech investor syndicate including Khosla Ventures, 8VC, Bioluminescence Ventures and the Cancer Research Institute

## Latest updates

- **2026-02** — Completed Phase 1 dosing of SRG-514 with no treatment-related dose-limiting toxicities; preparing to advance directly into a registrational trial in triple-negative breast cancer.
- **2023-07** — Closed $32M Series B led by Bioluminescence Ventures to advance the intraoperative immunotherapy platform and multiple clinical trials.
- **2023-01** — Received FDA clearance of its IND to initiate a Phase 1/2a study of intraoperative immunotherapy in bladder cancer.
- **2022-10** — Raised $26M Series A led by Camford Capital to accelerate development of intraoperative immunotherapy.

## Links

- Website: https://surgetx.com
- LinkedIn: https://www.linkedin.com/company/surge-therapeutics
- Twitter/X: https://x.com/SURGE_Tx_

---

Profile page: https://yespress.io/surge-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-11